한국인 치매환자에서의 리바스티그민 패취 사용 경험; 예비 연구

서지정보

· 발행기관 : 대한치매학회
· 수록지 정보 : Dementia and Neurocognitive Disorders(대한치매학회지) / 8권 / 1호 / 61 ~ 66페이지
· 저자명 : 나해리, 강현석, 김상석, 한설희

초록

While rivastigmine transdermal patch has consistently demonstrated better tolerability and
similar efficacy compared to conventional rivastigmine capsules in clinical studies; it has not
been specifically evaluated in Korean dementia patients. From February to November 2008,
94 patients with dementia and mild cognitive impairment (MCI) were treated with rivastigmine
transdermal patch at Konkuk University Hospital and Bobath Memorial Hospital. To evaluate
the safety and tolerability in Korean patients with dementia and MCI, we reviewed the clinical
data of the patients. The participating subjects were diagnosed as Alzheimer’s disease (n=
34), mild cognitive impairment (n=5), vascular dementia (n=26), Parkinson’s disease dementia
(n=13), dementia with Lewy body (n=3), frontotemporal dementia (n=2) and other types of
dementia (n=11). All of the patients were followed within 3 months (90±14 days), in terms of
evaluating adverse events. Adverse events occurred in 11 cases (11.7%) and adherence of
the patch was good in 91 cases (96.8%). Most of the participants showed clinical improvement
similar to other acetylcholinesterase inhibitors (AchEIs). The most common adverse effects
were skin-related problems including simple skin irritation, itching sensation, erythematous
lesion, patch marks (contact dermatitis) and even severe symptoms mixed with all of the
above (allergic contact dermatitis), occurred in eight cases (8.5%). Gastrointestinal (GI) discomfort
was reported in two cases (2.1%). Among patients who stopped rivastigmine transdermal
patch, six patients (6.3%) withdrew due to adverse events. Rivastigmine transdermal patch
provides a good tolerability profile in treating Korean patients with the various subtypes of dementia
and may be effective for the improvement of cognitive function in Korean patients with Alzheimer’s
disease.

참고자료

· 없음